| Needs review |
| 10.3390/Experiment 1 |
| 10.3390/microorganisms13071456/Experiment 1 |
| 10.3390/microorganisms13071456/Experiment 1 |
| A case report of malignant primary pericardial mesothelioma with atypical imaging appearance: multimodality imaging with histopathological correlation |
| A comparison of the gut microbiota among adult patients with drug-responsive and drug-resistant epilepsy: An exploratory study/Experiment 2 |
| A metagenomic study of the gut microbiome in PTB'S disease |
| A metagenomic study of the gut microbiome in PTB'S disease/Experiment 1 |
| A metagenomic study of the gut microbiome in PTB'S disease/Experiment 1/Signature 1 |
| A metagenomic study of the gut microbiome in PTB'S disease/Experiment 1/Signature 2 |
| Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status |
| Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status/Experiment 1 |
| Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status/Experiment 1/Signature 1 |
| Airway microbiome signature accurately discriminates Mycobacterium tuberculosis infection status/Experiment 1/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3/Signature 1 |
| Alteration in gut microbiota is associated with immune imbalance in Graves' disease |
| Alteration in gut microbiota is associated with immune imbalance in Graves' disease/Experiment 1 |
| Alteration in gut microbiota is associated with immune imbalance in Graves' disease/Experiment 1/Signature 1 |
| Alteration in gut microbiota is associated with immune imbalance in Graves' disease/Experiment 1/Signature 2 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1/Signature 1 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1/Signature 2 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 1/Signature 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 2 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 2/Signature 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 3 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 3/Signature 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 4 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 4/Signature 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 4/Signature 2 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 5 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 5/Signature 1 |
| Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis/Experiment 5/Signature 2 |
| Alterations in the intestinal microbiota associated with active tuberculosis and latent tuberculosis infection |
| Alterations in the intestinal microbiota associated with active tuberculosis and latent tuberculosis infection/Experiment 1 |
| Alterations in the intestinal microbiota associated with active tuberculosis and latent tuberculosis infection/Experiment 1/Signature 1 |
| Alterations in the intestinal microbiota associated with active tuberculosis and latent tuberculosis infection/Experiment 1/Signature 2 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 1 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 1/Signature 1 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 1/Signature 2 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 2 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 2/Signature 1 |
| Alterations of Gut Microbiome and Fecal Fatty Acids in Patients With Polycystic Ovary Syndrome in Central China/Experiment 2/Signature 2 |
| Alterations of Gut Microbiota in Patients With Graves' Disease |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 1 |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 1/Signature 1 |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 1/Signature 2 |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 2 |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 2/Signature 1 |
| Alterations of Gut Microbiota in Patients With Graves' Disease/Experiment 2/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 1 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4/Signature 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 1/Signature 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 1/Signature 2 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 2 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 2/Signature 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 3 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 3/Signature 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 3/Signature 2 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 4 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 4/Signature 1 |
| Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder/Experiment 4/Signature 2 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1/Signature 1 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1/Signature 2 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 2 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 2/Signature 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 2 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 2/Signature 1 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 1 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 1/Signature 1 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 1/Signature 2 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 2 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 2/Signature 1 |
| Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis/Experiment 2/Signature 2 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 1 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 1/Signature 1 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 1/Signature 2 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 2 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 2/Signature 1 |
| Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway/Experiment 2/Signature 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 1 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 2 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 1 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 1/Signature 1 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 1/Signature 2 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 2 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 2/Signature 1 |
| Analysis of oral microbiome in glaucoma patients using machine learning prediction models/Experiment 2/Signature 2 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 1 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 1/Signature 1 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 2 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 2/Signature 1 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 3 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 3/Signature 1 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 3/Signature 2 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 4 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 4/Signature 1 |
| Analysis of Salivary Microbiome in Patients with Alzheimer's Disease/Experiment 4/Signature 2 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 1 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 2 |
| Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals/Experiment 1/Signature 3 |
| APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease |
| APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease/Experiment 1 |
| APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease/Experiment 1/Signature 1 |
| APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease/Experiment 1/Signature 2 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 1 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 1/Signature 1 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 1/Signature 2 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 2 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 2/Signature 1 |
| Assessment of lower respiratory tract microbiota associated with pulmonary tuberculosis in children/Experiment 2/Signature 2 |
| Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies |
| Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies/Experiment 1 |
| Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies/Experiment 1/Signature 1 |
| Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies/Experiment 1/Signature 2 |
| Association between premature ovarian insufficiency and gut microbiota |
| Association between premature ovarian insufficiency and gut microbiota/Experiment 1 |
| Association between premature ovarian insufficiency and gut microbiota/Experiment 1/Signature 1 |
| Association between premature ovarian insufficiency and gut microbiota/Experiment 1/Signature 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1/Signature 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2/Signature 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3/Signature 2 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 1 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 1/Signature 1 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 1/Signature 2 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 2 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 2/Signature 1 |
| Association of cigarette smoking with oral bacterial microbiota and cardiometabolic health in Chinese adults/Experiment 2/Signature 2 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 1 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 1/Signature 1 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 1/Signature 2 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 2 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 2/Signature 1 |
| Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease/Experiment 2/Signature 2 |
| Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 2/Signature 1 |
| Body site-typical microbiome signatures for children/Experiment 2 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 1 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 2 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2/Signature 1 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2/Signature 2 |
| Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?-"BiotaCancerSurvivors": A Case-Control Study |
| Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?-"BiotaCancerSurvivors": A Case-Control Study/Experiment 1 |
| Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?-"BiotaCancerSurvivors": A Case-Control Study/Experiment 1/Signature 1 |
| Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?-"BiotaCancerSurvivors": A Case-Control Study/Experiment 1/Signature 2 |
| Breast tissue, oral and urinary microbiomes in breast cancer |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 1 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 1/Signature 1 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 1/Signature 2 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 2 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 2/Signature 1 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 3 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 3/Signature 1 |
| Breast tissue, oral and urinary microbiomes in breast cancer/Experiment 3/Signature 2 |
| Cannabis sativa L. alleviates loperamide-induced constipation by modulating the composition of gut microbiota in mice/Experiment 3 |
| Captive environments reshape the compositions of carbohydrate active enzymes and virulence factors in wolf gut microbiome |
| Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 1 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 1/Signature 1 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 1/Signature 2 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 2 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 2/Signature 1 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 2/Signature 2 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 3 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 3/Signature 1 |
| Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women/Experiment 3/Signature 2 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 1/Signature 1 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 1/Signature 2 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 2 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 2/Signature 1 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 2/Signature 2 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 3 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 3/Signature 1 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 3/Signature 2 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 4 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 4/Signature 1 |
| Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study/Experiment 4/Signature 2 |
| Changes in Gastrointestinal Microbiome Composition in PD: A Pivotal Role of Covariates/Experiment 3 |
| Changes in the gut microbiome associated with infliximab in patients with bipolar disorder |
| Changes in the gut microbiome associated with infliximab in patients with bipolar disorder/Experiment 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1/Signature 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1/Signature 2 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 2 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 1/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 2 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 2/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 2/Signature 2 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 3 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 3/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 4 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 4/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 5 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 5/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 6 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 6/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 7 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 7/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 8 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 8/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 9 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 9/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 10 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 10/Signature 1 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 11 |
| Changes in the vaginal microbiome during pregnancy and the postpartum period in South African women: a longitudinal study/Experiment 11/Signature 1 |
| Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosis |
| Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosis/Experiment 1 |
| Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosis/Experiment 1/Signature 1 |
| Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosis/Experiment 1/Signature 2 |
| Characteristics of the Gut Microbiota in Japanese Patients with Premenstrual Syndrome |
| Characteristics of the Gut Microbiota in Japanese Patients with Premenstrual Syndrome/Experiment 1 |
| Characteristics of the Gut Microbiota in Japanese Patients with Premenstrual Syndrome/Experiment 1/Signature 1 |
| Characteristics of the Gut Microbiota in Japanese Patients with Premenstrual Syndrome/Experiment 1/Signature 2 |
| Characteristics of the gut microbiota in women with premenstrual symptoms: A cross-sectional study |
| Characteristics of the gut microbiota in women with premenstrual symptoms: A cross-sectional study/Experiment 1 |
| Characteristics of the gut microbiota in women with premenstrual symptoms: A cross-sectional study/Experiment 1/Signature 1 |
| Characteristics of the gut microbiota in women with premenstrual symptoms: A cross-sectional study/Experiment 1/Signature 2 |
| Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection |
| Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection/Experiment 1 |
| Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection/Experiment 1/Signature 1 |
| Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection/Experiment 1/Signature 2 |
| Characteristics of the vaginal microbiome in women with premature ovarian insufficiency |
| Characteristics of the vaginal microbiome in women with premature ovarian insufficiency/Experiment 1 |
| Characteristics of the vaginal microbiome in women with premature ovarian insufficiency/Experiment 1/Signature 1 |
| Characteristics of the vaginal microbiome in women with premature ovarian insufficiency/Experiment 1/Signature 2 |
| Characteristics of Vaginal Microbiome in Women with Pelvic Inflammatory Disease in Korea |
| Characteristics of Vaginal Microbiome in Women with Pelvic Inflammatory Disease in Korea/Experiment 1 |
| Characteristics of Vaginal Microbiome in Women with Pelvic Inflammatory Disease in Korea/Experiment 1/Signature 1 |
| Characteristics of Vaginal Microbiome in Women with Pelvic Inflammatory Disease in Korea/Experiment 1/Signature 2 |
| Characterization of gut microbiota in children with pulmonary tuberculosis |
| Characterization of gut microbiota in children with pulmonary tuberculosis/Experiment 1 |
| Characterization of gut microbiota in children with pulmonary tuberculosis/Experiment 1/Signature 1 |
| Characterization of gut microbiota in children with pulmonary tuberculosis/Experiment 1/Signature 2 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 1 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 1/Signature 1 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 1/Signature 2 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 2 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 2/Signature 1 |
| Characterization of the gut microbiome in Alzheimer disease and mild cognitive impairment among older adults in Uganda: A case-control study/Experiment 2/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 1/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 1/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 2/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 2/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 3 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 3/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 3/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 4 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 4/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 5 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 5/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 5/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 6 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 6/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 6/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 7 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 7/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 8 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 8/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 8/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 9 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 9/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 10 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 10/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 11 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 11/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 12 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 12/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 12/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 13 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 13/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 13/Signature 2 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 14 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 14/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 15 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 15/Signature 1 |
| Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia/Experiment 15/Signature 2 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 1 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 1/Signature 1 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 2 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 2/Signature 1 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 3 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 3/Signature 1 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 4 |
| Characterization of the Vaginal Microbiome in Women with Infertility and Its Potential Correlation with Hormone Stimulation during In Vitro Fertilization Surgery/Experiment 4/Signature 1 |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study/Experiment 1 |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study/Experiment 1/Signature 1 |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study/Experiment 1/Signature 2 |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study/Experiment 2 |
| Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study/Experiment 2/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva |
| Classifying dementia progression using microbial profiling of saliva/Experiment 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 1/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 1/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 2/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 2/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 3 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 3/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 4 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 4/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 5 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 5/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 5/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 6 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 6/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 6/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 7 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 7/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 7/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 8 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 8/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 8/Signature 2 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 9 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 9/Signature 1 |
| Classifying dementia progression using microbial profiling of saliva/Experiment 9/Signature 2 |
| Clinical metagenomics analysis of bacterial and fungal microbiota from sputum of patients suspected with tuberculosis infection based on nanopore sequencing |
| Clinical metagenomics analysis of bacterial and fungal microbiota from sputum of patients suspected with tuberculosis infection based on nanopore sequencing/Experiment 1 |
| Clinical metagenomics analysis of bacterial and fungal microbiota from sputum of patients suspected with tuberculosis infection based on nanopore sequencing/Experiment 1/Signature 1 |
| Clinical metagenomics analysis of bacterial and fungal microbiota from sputum of patients suspected with tuberculosis infection based on nanopore sequencing/Experiment 1/Signature 2 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 1 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 1/Signature 1 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 1/Signature 2 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 2 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 2/Signature 1 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 2/Signature 2 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 3 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 3/Signature 1 |
| Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer: A preliminary study/Experiment 3/Signature 2 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 1 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 1/Signature 1 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 1/Signature 2 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 2 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 2/Signature 1 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 2/Signature 2 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 3 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 3/Signature 1 |
| Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy/Experiment 3/Signature 2 |
| Comparison of gut microbiota in autism spectrum disorders and neurotypical boys in China: A case-control study |
| Comparison of gut microbiota in autism spectrum disorders and neurotypical boys in China: A case-control study/Experiment 1 |
| Comparison of gut microbiota in autism spectrum disorders and neurotypical boys in China: A case-control study/Experiment 1/Signature 1 |
| Comparison of gut microbiota in autism spectrum disorders and neurotypical boys in China: A case-control study/Experiment 1/Signature 2 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 2 |
| Comprehensive Analysis of Pathogen Diversity and Diagnostic Biomarkers in Patients with Suspected Pulmonary Tuberculosis Through Metagenomic Next-Generation Sequencing |
| Comprehensive Analysis of Pathogen Diversity and Diagnostic Biomarkers in Patients with Suspected Pulmonary Tuberculosis Through Metagenomic Next-Generation Sequencing/Experiment 1 |
| Comprehensive Analysis of Pathogen Diversity and Diagnostic Biomarkers in Patients with Suspected Pulmonary Tuberculosis Through Metagenomic Next-Generation Sequencing/Experiment 1/Signature 1 |
| Comprehensive Analysis of Pathogen Diversity and Diagnostic Biomarkers in Patients with Suspected Pulmonary Tuberculosis Through Metagenomic Next-Generation Sequencing/Experiment 1/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 1/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 1/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 2/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 2/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 3 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 3/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 3/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 4 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 4/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 4/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 5 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 5/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 5/Signature 2 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 6 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 6/Signature 1 |
| Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 6/Signature 2 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 1 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 1/Signature 1 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 2 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 2/Signature 1 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 3 |
| Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer/Experiment 3/Signature 1 |
| Correlations between serum cytokines and gut microbiota in patients with Graves' disease: A case-control study |
| Correlations between serum cytokines and gut microbiota in patients with Graves' disease: A case-control study/Experiment 1 |
| Correlations between serum cytokines and gut microbiota in patients with Graves' disease: A case-control study/Experiment 1/Signature 1 |
| Correlations between serum cytokines and gut microbiota in patients with Graves' disease: A case-control study/Experiment 1/Signature 2 |
| Cross sectional observational, not case control |
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3/Signature 2 |
| Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1 |
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns/Experiment 1 |
| Diagnosis and insight into the unique lung microbiota of pediatric pulmonary tuberculosis patients by bronchoalveolar lavage using metagenomic next-generation sequencing |
| Diagnosis and insight into the unique lung microbiota of pediatric pulmonary tuberculosis patients by bronchoalveolar lavage using metagenomic next-generation sequencing/Experiment 1 |
| Diagnosis and insight into the unique lung microbiota of pediatric pulmonary tuberculosis patients by bronchoalveolar lavage using metagenomic next-generation sequencing/Experiment 1/Signature 1 |
| Diagnosis and insight into the unique lung microbiota of pediatric pulmonary tuberculosis patients by bronchoalveolar lavage using metagenomic next-generation sequencing/Experiment 1/Signature 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 1/Signature 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 1/Signature 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 2/Signature 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 2/Signature 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 3 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 3/Signature 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 3/Signature 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 4 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 4/Signature 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 4/Signature 2 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 5 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 5/Signature 1 |
| Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice/Experiment 5/Signature 2 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 1 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 1/Signature 1 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 1/Signature 2 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 2 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 2/Signature 1 |
| Differences in the eyelid and buccal microbiome between open-angle glaucoma and uveitic glaucoma/Experiment 2/Signature 2 |
| Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4/Signature 2 |
| Differences in the gut microbiota between Gurkhas and soldiers of British origin |
| Differences in the gut microbiota between Gurkhas and soldiers of British origin/Experiment 1 |
| Differences in the gut microbiota between Gurkhas and soldiers of British origin/Experiment 1/Signature 1 |
| Differences in the gut microbiota between Gurkhas and soldiers of British origin/Experiment 1/Signature 2 |
| Differences in the gut microbiota between Gurkhas and soldiers of British origin/Experiment 2 |
| Different Efficacy of Five Soluble Dietary Fibers on Alleviating Loperamide-Induced Constipation in Mice: Influences of Different Structural Features/Experiment 9/Signature 1 |
| Different Efficacy of Five Soluble Dietary Fibers on Alleviating Loperamide-Induced Constipation in Mice: Influences of Different Structural Features/Experiment 14/Signature 1 |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients/Experiment 6/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 11 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 11/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 12 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 12/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 13 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 13/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17/Signature 2 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 1 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 1/Signature 1 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 2 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 2/Signature 1 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 3 |
| Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus/Experiment 3/Signature 1 |
| Disorders of Gut Microbiota and Plasma Metabolic Profiles May Be Associated with Lymph Node Tuberculosis |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 1 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 1/Signature 1 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 2 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 2/Signature 1 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 3 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 3/Signature 1 |
| Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice/Experiment 3/Signature 2 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 1 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 1/Signature 1 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 1/Signature 2 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 2 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 2/Signature 1 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 2/Signature 2 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 3 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 3/Signature 1 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 3/Signature 2 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 4 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 4/Signature 1 |
| Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients/Experiment 4/Signature 2 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 1 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 1/Signature 1 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 1/Signature 2 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 2 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 2/Signature 1 |
| Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis/Experiment 2/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 1/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 1/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 2/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 2/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 3 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 3/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 4 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 4/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 4/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 5 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 5/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 5/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 6 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 6/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 6/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 7 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 7/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 7/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 8 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 8/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 8/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 9 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 9/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 9/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 10 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 10/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 10/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 11 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 11/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 11/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 12 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 12/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 12/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 13 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 13/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 14 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 14/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 15 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 15/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 15/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 16 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 16/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 16/Signature 2 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 17 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 17/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 18 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 18/Signature 1 |
| Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition/Experiment 18/Signature 2 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 1 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 2 |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 2/Signature 1 |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 4 |
| Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1/Signature 2 |
| Establishment of the early gut microbiota in vaginally delivered infants: the influence of maternal gut microbiota outweighs vaginal microbiota |
| Excess fermentation and lactic acidosis as detrimental functions of the gut microbes in treatment-naive TB patients |
| Excess fermentation and lactic acidosis as detrimental functions of the gut microbes in treatment-naive TB patients/Experiment 1 |
| Excess fermentation and lactic acidosis as detrimental functions of the gut microbes in treatment-naive TB patients/Experiment 1/Signature 1 |
| Excess fermentation and lactic acidosis as detrimental functions of the gut microbes in treatment-naive TB patients/Experiment 1/Signature 2 |
| Exclusive enteral nutrition initiates individual protective microbiome changes to induce remission in pediatric Crohn's disease/Experiment 18/Signature 2 |
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 4 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 8 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 10 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 11 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 15 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 20 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25/Signature 1 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 1 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 1/Signature 1 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 1/Signature 2 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 2 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 2/Signature 1 |
| Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study/Experiment 2/Signature 2 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 1 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 1/Signature 1 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 1/Signature 2 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 2 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 2/Signature 1 |
| Features of vaginal microbiota in women with vulvovaginal candidiasis/Experiment 2/Signature 2 |
| Fecal Microbiota Changes in Patients With Postpartum Depressive Disorder |
| Fecal Microbiota Changes in Patients With Postpartum Depressive Disorder/Experiment 1 |
| Fecal Microbiota Changes in Patients With Postpartum Depressive Disorder/Experiment 1/Signature 1 |
| Fecal Microbiota Changes in Patients With Postpartum Depressive Disorder/Experiment 1/Signature 2 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 1/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 1/Signature 2 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 2 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 2/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 2/Signature 2 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 3 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 3/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 4 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 4/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 4/Signature 2 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 5 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 5/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 6 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 6/Signature 1 |
| Fermented foods affect the seasonal stability of gut bacteria in an Indian rural population/Experiment 6/Signature 2 |
| Gut bacterial and fungal dysbiosis in tuberculosis patients |
| Gut bacterial and fungal dysbiosis in tuberculosis patients/Experiment 1 |
| Gut bacterial and fungal dysbiosis in tuberculosis patients/Experiment 1/Signature 1 |
| Gut bacterial and fungal dysbiosis in tuberculosis patients/Experiment 1/Signature 2 |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders/Experiment 1 |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders/Experiment 2 |
| Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders/Experiment 2/Signature 1 |
| Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 7/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 1/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 2/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 3 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 3/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 3/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 6 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 6/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 7 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 7/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 8 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 8/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 9 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 9/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 10 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 10/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 11 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 11/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 12 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 12/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 13 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 13/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 14 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 14/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 15 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 15/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 1/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 1/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 2/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 2/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 3 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 3/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 3/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 4 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 4/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 4/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 5 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 5/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 5/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 6 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 6/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 6/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 7 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 7/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 7/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 8 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 8/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 8/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 9 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 9/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 9/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 10 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 10/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 10/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 11 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 11/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 11/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 12 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 12/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 13 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 13/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 13/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 14 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 14/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 15 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 15/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 16 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 16/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 16/Signature 2 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 17 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 17/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 18 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 18/Signature 1 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 19 |
| Gut microbiome alterations precede graft rejection in kidney transplantation patients/Experiment 19/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 1/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 1/Signature 2 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 2 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 2/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 2/Signature 2 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 3 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 3/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 3/Signature 2 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 4 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 4/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 5 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 5/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 6 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 6/Signature 1 |
| Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study/Experiment 6/Signature 2 |
| Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 5 |
| Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting |
| Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting/Experiment 1 |
| Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting/Experiment 1/Signature 1 |
| Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting/Experiment 1/Signature 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1/Signature 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1/Signature 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2/Signature 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2/Signature 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 3 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 3/Signature 1 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 1 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 1/Signature 1 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 1/Signature 2 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 2 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 2/Signature 1 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 2/Signature 2 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 3 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 3/Signature 1 |
| Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals/Experiment 3/Signature 2 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 1 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 1/Signature 1 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 2 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 2/Signature 1 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 3 |
| Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis/Experiment 3/Signature 1 |
| Gut microbiota changes in patients with autism spectrum disorders |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1 |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1/Signature 1 |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1/Signature 2 |
| Gut microbiota composition can reflect immune responses of latent tuberculosis infection in patients with poorly controlled diabetes |
| Gut microbiota composition can reflect immune responses of latent tuberculosis infection in patients with poorly controlled diabetes/Experiment 1 |
| Gut microbiota composition can reflect immune responses of latent tuberculosis infection in patients with poorly controlled diabetes/Experiment 1/Signature 1 |
| Gut microbiota composition can reflect immune responses of latent tuberculosis infection in patients with poorly controlled diabetes/Experiment 1/Signature 2 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 1 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 2 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 2/Signature 1 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 2/Signature 2 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 3 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 3/Signature 1 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 4 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 4/Signature 1 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 4/Signature 2 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 5 |
| Gut microbiota composition differences are associated with geographic location and age in malaria-endemic regions of Rwanda/Experiment 5/Signature 1 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 1 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 2 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 2/Signature 1 |
| Gut Microbiota Features in Young Children With Autism Spectrum Disorders/Experiment 2/Signature 2 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 1 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 1/Signature 1 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 1/Signature 2 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 2 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 2/Signature 1 |
| Gut Microbiota May Play a Significant Role in the Pathogenesis of Graves' Disease/Experiment 2/Signature 2 |
| Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors/Experiment 3/Signature 1 |
| Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors/Experiment 3/Signature 2 |
| Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors/Experiment 4/Signature 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1/Signature 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1/Signature 2 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2/Signature 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2/Signature 2 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 3 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 3/Signature 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4/Signature 1 |
| Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4/Signature 2 |
| Gut microbiota: impacts on gastrointestinal cancer immunotherapy/Experiment 1/Signature 2 |
| Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment |
| Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment/Experiment 1 |
| Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment/Experiment 1/Signature 1 |
| Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment/Experiment 1/Signature 2 |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1 |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1/Signature 2 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 12 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 12/Signature 1 |
| [1/Signature 1|Https://doi.org] |
| [2/Signature 1|Https://doi.org] |
| [[1]] |
| [[2]] |
| [[3]] |
| [1|Https:/Experiment 1] |
| [2|Https:/Experiment 2] |
| [3|Https:/Experiment 3] |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 2 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 2 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 2/Signature 1 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 2/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 22 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 23 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 24 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 46 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 47 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 48 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69/Signature 2 |
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1 |
| Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis/Experiment 1 |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 1 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 1/Signature 1 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 1/Signature 2 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 2 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 2/Signature 1 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 2/Signature 2 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 3 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 3/Signature 1 |
| Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection/Experiment 3/Signature 2 |
| 40914795/Experiment 4 |
| 40914795/Experiment 4/Signature 1 |
| 40914795/Experiment 4/Signature 2 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 1 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 1/Signature 1 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 1/Signature 2 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 2 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 2/Signature 1 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 2/Signature 2 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 3 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 3/Signature 1 |
| Integrated microbiome and metabolome analysis reveals a distinct microbial and metabolic signature in Graves' disease and hypothyroidism/Experiment 3/Signature 2 |
| Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis |
| Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1/Signature 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2/Signature 1 |
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1 |
| Intestinal microbiota changes in Graves' disease: a prospective clinical study |
| Intestinal microbiota changes in Graves' disease: a prospective clinical study/Experiment 1 |
| Intestinal microbiota changes in Graves' disease: a prospective clinical study/Experiment 1/Signature 1 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3/Signature 2 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 1/Signature 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 2 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 2/Signature 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 3 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 3/Signature 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 4 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 4/Signature 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 5 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 5/Signature 1 |
| Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics/Experiment 6/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1/Signature 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2/Signature 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 3 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 3/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 4 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 4/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 5 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 5/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 1/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 1/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 2/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 2/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 3 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 3/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 3/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 4 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 4/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 4/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 5 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 5/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 5/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 6 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 6/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 7 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 7/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 8 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 8/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 9 |
| Ketogenic Diets Alter the Gut Microbiome, Resulting in Decreased Susceptibility to and Cognitive Impairment in Rats with Pilocarpine-Induced Status Epilepticus/Experiment 9/Signature 1 |
| Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life |
| Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life/Experiment 1 |
| Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life/Experiment 1/Signature 1 |
| Ketogenic Diets in Children With Intractable Epilepsy and its Effects on Gastrointestinal Function, Gut Microbiome, Inflammation, and Quality of Life/Experiment 1/Signature 2 |
| Left atrial geometry and outcome of atrial fibrillation ablation: results from the multicentre LAGO-AF study |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 1 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 2 |
| Linking long-term dietary patterns with gut microbial enterotypes |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2 |
| Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects |
| Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 6/Signature 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 2 |
| Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 6 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 1 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 1/Signature 1 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 1/Signature 2 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 2 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 2/Signature 1 |
| Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease/Experiment 2/Signature 2 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 2 |
| Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 2/Signature 1 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 2 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 3 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 4 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 1 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 2 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 3 |
| Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation |
| Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation/Experiment 1 |
| Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation/Experiment 1/Signature 1 |
| Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation/Experiment 1/Signature 2 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 1 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 1/Signature 1 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 1/Signature 2 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 2 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 2/Signature 1 |
| Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome/Experiment 2/Signature 2 |
| Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation/Experiment 1 |
| Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study |
| Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study/Experiment 1 |
| Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study/Experiment 1/Signature 1 |
| Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study/Experiment 1/Signature 2 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 1/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 1/Signature 2 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 2 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 2/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 3 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 3/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 4 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 4/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 4/Signature 2 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 5 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 5/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 6 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 6/Signature 1 |
| Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues/Experiment 6/Signature 2 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 2 |
| Microbial communities associated with honey bees in Brazil and in the United States |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 2 |
| Microbiome Alteration in Lung Tissues of Tuberculosis Patients Revealed by Metagenomic Next-Generation Sequencing and Immune-Related Transcriptional Profile Identified by Transcriptome Sequencing |
| Microbiome Alteration in Lung Tissues of Tuberculosis Patients Revealed by Metagenomic Next-Generation Sequencing and Immune-Related Transcriptional Profile Identified by Transcriptome Sequencing/Experiment 1 |
| Microbiome Alteration in Lung Tissues of Tuberculosis Patients Revealed by Metagenomic Next-Generation Sequencing and Immune-Related Transcriptional Profile Identified by Transcriptome Sequencing/Experiment 1/Signature 1 |
| Microbiome Alteration in Lung Tissues of Tuberculosis Patients Revealed by Metagenomic Next-Generation Sequencing and Immune-Related Transcriptional Profile Identified by Transcriptome Sequencing/Experiment 1/Signature 2 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 3 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 1 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 2 |
| Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women |
| Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women/Experiment 1 |
| Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women/Experiment 1/Signature 1 |
| Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women/Experiment 1/Signature 2 |
| Microbiome diversity in the sputum of patients with pulmonary tuberculosis |
| Microbiome diversity in the sputum of patients with pulmonary tuberculosis/Experiment 1 |
| Microbiome diversity in the sputum of patients with pulmonary tuberculosis/Experiment 1/Signature 1 |
| Microbiome diversity in the sputum of patients with pulmonary tuberculosis/Experiment 1/Signature 2 |
| Microbiome diversity in the sputum of patients with pulmonary tuberculosis/Experiment 2 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 1 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 1 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 2 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 1 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 1/Signature 1 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 1/Signature 2 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 2 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 2/Signature 1 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 2/Signature 2 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 3 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 3/Signature 1 |
| Microbiota composition in bilateral healthy breast tissue and breast tumors/Experiment 3/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 1/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 1/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 2/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 2/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 3 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 3/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 3/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 4 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 4/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 4/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 5 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 5/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 5/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 6 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 6/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 6/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 7 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 7/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 7/Signature 2 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 8 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 8/Signature 1 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota/Experiment 8/Signature 2 |
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 13/Signature 2 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 1/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 2 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 2/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 3 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 3/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 4 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 4/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 4/Signature 2 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 5 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 5/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 5/Signature 2 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 6 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 6/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 7 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 7/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 7/Signature 2 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 8 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 8/Signature 1 |
| Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 8/Signature 2 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 1/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 1/Signature 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 2/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 2/Signature 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 3 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 3/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 3/Signature 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 4 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 4/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 4/Signature 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 5 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 5/Signature 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 1/Signature 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 2 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 2/Signature 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 3 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 3/Signature 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 4 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 4/Signature 1 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 5 |
| Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome/Experiment 5/Signature 1 |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients/Experiment 1 |
| Newly identified species from the dog dental plaque microbiome highlight little overlap with humans |
| Newly identified species from the dog dental plaque microbiome highlight little overlap with humans/Experiment 1 |
| Newly identified species from the dog dental plaque microbiome highlight little overlap with humans/Experiment 1/Signature 1 |
| Newly identified species from the dog dental plaque microbiome highlight little overlap with humans/Experiment 1/Signature 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1/Signature 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2/Signature 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3/Signature 2 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 1 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 1/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 1/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 2/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 2/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 3 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 3/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 3/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 4 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 4/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 4/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 5 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 5/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 6 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 6/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 6/Signature 2 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 7 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 7/Signature 1 |
| Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer/Experiment 7/Signature 2 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 1 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 1/Signature 1 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 1/Signature 2 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 2 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 2/Signature 1 |
| Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease/Experiment 2/Signature 2 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 1 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 7/Signature 2 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 1 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 2 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 6/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 8/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 16/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 17/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 17/Signature 2 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 19/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 20/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 1/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 1/Signature 2 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 2 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 2/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 3 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 3/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 4 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 4/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 5 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 5/Signature 1 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 5/Signature 2 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 6 |
| Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota/Experiment 6/Signature 1 |
| Peripheral blood microbiome signature and Mycobacterium tuberculosis-derived rsRNA as diagnostic biomarkers for tuberculosis in human |
| Peripheral blood microbiome signature and Mycobacterium tuberculosis-derived rsRNA as diagnostic biomarkers for tuberculosis in human/Experiment 1 |
| Peripheral blood microbiome signature and Mycobacterium tuberculosis-derived rsRNA as diagnostic biomarkers for tuberculosis in human/Experiment 1/Signature 1 |
| Peripheral blood microbiome signature and Mycobacterium tuberculosis-derived rsRNA as diagnostic biomarkers for tuberculosis in human/Experiment 1/Signature 2 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 1 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 2 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1/Signature 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2/Signature 1 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 1 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 1/Signature 1 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 1/Signature 2 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 2 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 2/Signature 1 |
| Preliminary characterization of gut mycobiome enterotypes reveals the correlation trends between host metabolic parameter and diet: a case study in the Thai Cohort/Experiment 2/Signature 2 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 2 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 1 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 2 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 1 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 1/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 1/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 2/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 2/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 3 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 3/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 3/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 4 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 4/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 4/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 5 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 5/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 5/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 6 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 6/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 7 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 7/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 7/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 8 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 8/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 8/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 9 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 9/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 9/Signature 2 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 10 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 10/Signature 1 |
| Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 10/Signature 2 |
| Progression of gut microbiome in preterm infants during the first three months |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 1 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 2 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 1 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 2 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2/Signature 1 |
| Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1/Signature 2 |
| Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects |
| Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects/Experiment 1 |
| Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects/Experiment 1/Signature 1 |
| Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects/Experiment 1/Signature 2 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 1 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 1/Signature 1 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 1/Signature 2 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 2 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 2/Signature 1 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 2/Signature 2 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 3 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 3/Signature 1 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 3/Signature 2 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 4 |
| Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children/Experiment 4/Signature 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 2 |
| Reduced microbiome alpha diversity in young patients with ADHD |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 2 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 2 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 1 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 1/Signature 1 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 1/Signature 2 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 3 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 3/Signature 1 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 3/Signature 2 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 4 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 4/Signature 1 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 5 |
| Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer/Experiment 5/Signature 1 |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease/Experiment 1 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 1/Signature 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2/Signature 1 |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 2 |
| Rifaximin reduces gut-derived inflammation in severe acute pancreatitis: an experimental animal model and randomized controlled trial |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition/Experiment 1 |
| Shift in skin microbiota of Western European women across aging |
| Shift in skin microbiota of Western European women across aging/Experiment 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 2 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 2 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 2 |
| Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study |
| Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study/Experiment 1 |
| Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study/Experiment 1/Signature 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2/Signature 1 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1/Signature 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 2 |
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4 |
| Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment |
| Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment/Experiment 1 |
| Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment/Experiment 1/Signature 1 |
| Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment/Experiment 1/Signature 2 |
| Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy |
| Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy/Experiment 1 |
| Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy/Experiment 1/Signature 1 |
| Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy/Experiment 1/Signature 2 |
| Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-line therapy/Experiment 2 |
| Study 11 |
| Study 11/Experiment 1 |
| Study 11/Experiment 1/Signature 1 |
| Study 39 |
| Study 39/Experiment 1 |
| Study 39/Experiment 1/Signature 1 |
| Study 39/Experiment 1/Signature 2 |
| Study 39/Experiment 2 |
| Study 39/Experiment 2/Signature 1 |
| Study 39/Experiment 3 |
| Study 39/Experiment 3/Signature 1 |
| Study 84 |
| Study 84/Experiment 1 |
| Study 84/Experiment 1/Signature 1 |
| Study 84/Experiment 1/Signature 2 |
| Study 501 |
| Study 501/Experiment 1 |
| Study 501/Experiment 1/Signature 1 |
| Study 919/Experiment 1 |
| Study 919/Experiment 1/Signature 1 |
| Study 919/Experiment 1/Signature 2 |
| Study 1030 |
| Study 1098 |
| Study 1112 |
| Study 1120 |
| Study 1128 |
| Study 1134 |
| Study 1136 |
| Study 1137 |
| Study 1138 |
| Study 1153 |
| Study 1154 |
| Study 1155 |
| Study 1164 |
| Study 1171 |
| Study 1199 |
| Study 1273 |
| Study 1274 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 2 |
| Study on the diversity and difference of intratumoral flora in patients with triple negative breast cancer |
| Study on the diversity and difference of intratumoral flora in patients with triple negative breast cancer/Experiment 1 |
| Study on the diversity and difference of intratumoral flora in patients with triple negative breast cancer/Experiment 1/Signature 1 |
| Study on the diversity and difference of intratumoral flora in patients with triple negative breast cancer/Experiment 1/Signature 2 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1/Signature 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 2 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 1 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 1/Signature 1 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 2 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 2/Signature 1 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 3 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 3/Signature 1 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 4 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 4/Signature 1 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 5 |
| Suppression of MyD88 disturbs gut microbiota and activates the NLR pathway and hence fails to ameliorate DSS-induced colitis/Experiment 5/Signature 1 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7/Signature 1 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 1 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 1/Signature 1 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 2 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 2/Signature 1 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 2/Signature 2 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 3 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 3/Signature 1 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 3/Signature 2 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 4 |
| Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls/Experiment 4/Signature 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 2 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 3 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 4 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 5 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 6 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 7 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 2 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 3 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 4 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 1 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 1/Signature 1 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 1/Signature 2 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 2 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 2/Signature 1 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 2/Signature 2 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 3 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 3/Signature 1 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 3/Signature 2 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 4 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 4/Signature 1 |
| The association between the gut microbiome and antituberculosis drug-induced liver injury/Experiment 4/Signature 2 |
| The biogeography of the mucosa-associated microbiome in health and disease/Experiment 15 |
| The biogeography of the mucosa-associated microbiome in health and disease/Experiment 15/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 2 |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial/Experiment 1 |
| The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 4 |
| The dynamics of the gut microbiota in prediabetes during a four-year follow-up among European patients-an IMI-DIRECT prospective study |
| The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 2/Signature 1 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 1 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 1/Signature 1 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 1/Signature 2 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 2 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 2/Signature 1 |
| The gut dysbiosis and plasma lipid metabolisms signatures in children with active tuberculosis/Experiment 2/Signature 2 |
| The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 2 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 2/Signature 2 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 1 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 1/Signature 1 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 1/Signature 2 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 2 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 2/Signature 1 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 2/Signature 2 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 3 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 3/Signature 1 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 3/Signature 2 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 4 |
| The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet/Experiment 4/Signature 1 |
| The impact of anti-tuberculosis treatment on respiratory tract microbiome in pulmonary tuberculosis |
| The impact of anti-tuberculosis treatment on respiratory tract microbiome in pulmonary tuberculosis/Experiment 1 |
| The impact of anti-tuberculosis treatment on respiratory tract microbiome in pulmonary tuberculosis/Experiment 1/Signature 1 |
| The impact of anti-tuberculosis treatment on respiratory tract microbiome in pulmonary tuberculosis/Experiment 1/Signature 2 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 1 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 1/Signature 1 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 1/Signature 2 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 2 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 2/Signature 1 |
| The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma/Experiment 2/Signature 2 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 1 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 1/Signature 1 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 1/Signature 2 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 2 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 2/Signature 1 |
| The Microbiota of Breast Tissue and Its Association with Breast Cancer/Experiment 2/Signature 2 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 1 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 2 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 3 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 4 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 5 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 6 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 7 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 8 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 9 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 10 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 11 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 12 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 13 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 14 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 15 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 16 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 17 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 18 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 19 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 20 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 21 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 22 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 23 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 24 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 25 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 26 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 27 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 28 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 29 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 30 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 31 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 32 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 33 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 34 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 35 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 36 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 37 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 38 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 39 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 40 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 41 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 42 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 43 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 44 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 45 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 46 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 47 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 48 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 49 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 50 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 51 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 52 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 53 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 54 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 55 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 56 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 57 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 58 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 59 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 60 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 61 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 62 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 63 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 64 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 65 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 66 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 67 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 68 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 69 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 70 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 71 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 72 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 73 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 74 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 75 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 76 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 77 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 78 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 79 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 80 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 81 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 82 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 83 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 84 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 85 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 86 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 87 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 88 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 89 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 90 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 91 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 92 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 93 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 94 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 95 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 96 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 97 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 98 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 99 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 100 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 101 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 102 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 103 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 104 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 105 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 106 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 107 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 108 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 109 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 110 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 111 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 112 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 113 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 114 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 115 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 116 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 117 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 118 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 119 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 120 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 121 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 122 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 123 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 124 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 125 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 126 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 127 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 128 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 129 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 130 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 131 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 132 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 133 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 134 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 135 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 136 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 137 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 138 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 139 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 140 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 141 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 142 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 143 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 144 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 145 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 146 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 147 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 148 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 149 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 150 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 151 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 152 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 153 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 154 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 155 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 156 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 157 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 158 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 159 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 160 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 161 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 162 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 163 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 164 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 165 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 166 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 167 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 168 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 169 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 170 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 171 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 172 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 173 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 174 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 175 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 176 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 177 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 178 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 179 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 180 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 181 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 182 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 183 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 184 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 185 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 186 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 187 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 188 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 189 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 190 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 191 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 192 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 193 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 194 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 195 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 196 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 197 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 198 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 199 |
| The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors/Experiment 200 |
| The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder/Experiment 4/Signature 2 |
| The nasal microbiome in asthma/Experiment 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3/Signature 1 |
| The oral microbiome of newly diagnosed tuberculosis patients; a pilot study |
| The oral microbiome of newly diagnosed tuberculosis patients; a pilot study/Experiment 1 |
| The oral microbiome of newly diagnosed tuberculosis patients; a pilot study/Experiment 1/Signature 1 |
| The oral microbiome of newly diagnosed tuberculosis patients; a pilot study/Experiment 1/Signature 2 |
| The oral microbiome of newly diagnosed tuberculosis patients; a pilot study/Experiment 2 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4/Signature 1 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 1 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 1/Signature 1 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 2 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 2/Signature 1 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 3 |
| The potential mechanism of the progression from latent to active tuberculosis based on the intestinal microbiota alterations/Experiment 3/Signature 1 |
| The relationship between menopausal syndrome and gut microbes |
| The relationship between menopausal syndrome and gut microbes/Experiment 1 |
| The relationship between menopausal syndrome and gut microbes/Experiment 1/Signature 1 |
| The relationship between menopausal syndrome and gut microbes/Experiment 1/Signature 2 |
| The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder |
| The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder/Experiment 1 |
| The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder/Experiment 1/Signature 1 |
| The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder/Experiment 1/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 2 |
| The Urinary Microbiome in Women Using Single-Use Versus Reusable Catheters for Intermittent Catheterization: An Exploratory Substudy of the COMPaRE Trial |
| The Urinary Microbiome in Women Using Single-Use Versus Reusable Catheters for Intermittent Catheterization: An Exploratory Substudy of the COMPaRE Trial/Experiment 1 |
| The Urinary Microbiome in Women Using Single-Use Versus Reusable Catheters for Intermittent Catheterization: An Exploratory Substudy of the COMPaRE Trial/Experiment 1/Signature 1 |
| The Urinary Microbiome in Women Using Single-Use Versus Reusable Catheters for Intermittent Catheterization: An Exploratory Substudy of the COMPaRE Trial/Experiment 1/Signature 2 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 1 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 1/Signature 1 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 1/Signature 2 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 2 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 2/Signature 1 |
| To explore the mechanism of acupoint application in the treatment of primary dysmenorrhea by 16S rDNA sequencing and metabolomics/Experiment 2/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 1/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 2/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 2/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 3 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 3/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 4 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 4/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 4/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 5 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 5/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 5/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 6 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 6/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 6/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 7 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 7/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 7/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 8 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 8/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 8/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 9 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 9/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 9/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 10 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 10/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 10/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 11 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 11/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 11/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 12 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 12/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 12/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 13 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 13/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 13/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 14 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 14/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 14/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 15 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 15/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 15/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 16 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 16/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 16/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 17 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 17/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 17/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 18 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 18/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 18/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 19 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 19/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 19/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 20 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 20/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 20/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 21 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 21/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 21/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 22 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 22/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 23 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 23/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 24 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 24/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 25 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 25/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 25/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 26 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 26/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 26/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 27 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 27/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 27/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 28 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 28/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 28/Signature 2 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 29 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 29/Signature 1 |
| Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 29/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 1/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 1/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 2/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 2/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 3 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 3/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 3/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 4 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 4/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 4/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 5 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 5/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 5/Signature 2 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 6 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 6/Signature 1 |
| Uncovering Microbial Composition in Human Breast Cancer Primary Tumour Tissue Using Transcriptomic RNA-seq/Experiment 6/Signature 2 |
| Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer |
| Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer/Experiment 1 |
| Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer/Experiment 1/Signature 1 |
| Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer/Experiment 2 |
| Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer/Experiment 2/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 1/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 1/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 2/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 2/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 3 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 3/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 4 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 4/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 5 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 5/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 6 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 6/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 7 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 7/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 8 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 8/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 9 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 9/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 10 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 10/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 11 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 11/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 12 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 12/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 13 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 13/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 13/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 14 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 14/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 14/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 15 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 15/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 16 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 16/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 17 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 17/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 18 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 18/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 19 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 19/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 20 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 20/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 20/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 21 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 21/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 21/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 22 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 22/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 22/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 23 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 23/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 23/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 24 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 24/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 24/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 25 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 25/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 25/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 26 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 26/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 26/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 27 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 27/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 27/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 28 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 28/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 28/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 29 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 29/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 29/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 30 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 30/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 30/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 31 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 31/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 31/Signature 2 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 32 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 32/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 33 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 33/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 34 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 34/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 35 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 35/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 36 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 36/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 37 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 37/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 38 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 38/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 39 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 39/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 40 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 40/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 41 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 41/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 42 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 42/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 43 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 43/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 44 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 44/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 45 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 45/Signature 1 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 46 |
| Why do babies cry? Exploring the role of the gut microbiota in infantile colic, constipation, and cramps in the KOALA birth cohort study/Experiment 46/Signature 1 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 1 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 1/Signature 1 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 1/Signature 2 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 2 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 2/Signature 1 |
| Yanomami skin microbiome complexity challenges prevailing concepts of healthy skin/Experiment 2/Signature 2 |
